All news from R&D

Organ-on-Chip Research Accelerated by New European Society Launching, Finding

The new European Organ-on-Chip Society (EUROoCS) was officially launched at the third International Organ-on-Chip Symposium, held on 8 and 9 November 2018 at the University of Technology in Eindhoven, the Netherlands.

The Society will encourage development and coordination of Organ-on-Chip research in Europe in support of better health for all. Membership will be open from 2019 to all researchers in the field, providing access benefits to the pending digital Organ-on-Chip platform, the annual meeting and the future society journal.

Preclinical Studies: Synthetic DMAbs Protect Against Ebola

Scientists at The Wistar Institute and collaborators have successfully engineered novel DNA-encoded monoclonal antibodies (DMAbs) targeting Zaire Ebolavirus that were effective in preclinical models. Study results, published online in  Cell Reports, showed that DMAbs were expressed over a wide window of time and offered complete and long-term protection against lethal virus challenges.

DMAbs may also provide a novel powerful platform for rapid screening of monoclonal antibodies enhancing preclinical development. The Weiner Laboratory is also developing an anti-Ebola virus DNA vaccine. Preclinical results from this were published recently in the  Journal of Infectious Diseases .

Light-transducing Nanoparticles: Scientists Succeed in Increasing Stability, Biocompatibility

A team of scientists from the Helmholtz-Zentrum Dresden-Rossendorf (HZDR), in collaboration with researchers from Monash University Australia, has succeeded in significantly increasing the stability and biocompatibility of special light-transducing nanoparticles.

The team has developed the so-called "upconverting" nanoparticles that do not only convert infrared light into UV-visible light, but also are water-soluble, remain stable in complex body fluids such as blood serum, and can be used to store medications. They have created a tool that could potentially make the fight against cancer significantly more effective. The researchers recently published their results in the journal  Angewandte Chemie

Antimicrobial Nanoparticles in Kitchen? New Findings

Scientists describe how they simulated knife motion, washing and scratching on bacteria-fighting, nanosilver-infused cutting boards to see if consumer use affects nanoparticle release. The test should help regulatory bodies identify if any safety or health risks exist from silver nanoparticles in kitchenware now being sold overseas, and if so, find ways to deal with them before the items are approved for sale in the United States.

Research in the Field of Commensal Microbiota, Study

The winner of the Johanna Duermueller-Bol DBMR Research Award 2018 is Dr. Stephanie Ganal-Vonarburg. As a Senior Scientist, she conducts research in the Gastroenterology / Mucosal Immunology Research Laboratory at Bern University Hospital and at the Department for BioMedical Research at the University of Bern. Ganal-Vonarburg is being awarded for its research in the field of commensal microbiota – the microbes in the intestine.

Targeted Drug Extends Breast Cancer Survival, Research Trials

Combining a targeted drug with hormone therapy completes survival for women with advanced breast cancer, a major clinical trial has found. Women taking  palbociclib  together with hormone therapy lived seven months longer than those on hormone treatment alone – adding to previous data showing the combination could delay the disease progression.

We're doing drug trials wrong – here's how to fix it

By the age of 65, at least half of us will suffer from two or more long-term diseases. And the chance of having multi-morbidity, as it is known, increases with age. Only 9% of people with coronary heart disease have no other condition. The other 91% have various combinations of hypertension (high blood pressure), heart failure, stroke, diabetes, chronic obstructive pulmonary disease, depression, dementia, chronic kidney disease and so on.